Evolution of Primary HIV Drug Resistance in a Subtype C Dominated Epidemic in Mozambique

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Bila, Dulce Celina Adolfo ^a,b   Young, Peter ^c   Merks, Harriet ^d   Vubil, Adolfo Salvador ^a   Mahomed, Mussagy ^a   Augusto, Angelo ^a   Abreu, Celina Monteiro ^b   Mabunda, Nédio Jonas ^a   Brooks, James I ^d,e   Tanuri, Amilcar ^b   Jani, Ilesh Vinodrai ^a  

^a INSTITUTO NACIONAL DE SAÚDE   (Mozambique)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; DISEASE ASSOCIATION; DRUG EFFICACY; EPIDEMIC; FEMALE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1C; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MOZAMBIQUE; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PREGNANT WOMAN; PRENATAL CARE; TRANSMITTED DRUG RESISTANCE;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MOZAMBIQUE; MUTATION; PHYLOGENY; PREGNANCY; YOUNG ADULT;

EID: 84880772571     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068213     Document Type: Article

References (27)

1. UNAIDS (2012) UNAIDS Report on the global AIDS epidemic. [online]. Disponível na URL: http://www.unaids.org/globalreport/default.htm [Acessado em 03 de Maio de 2013].
2. MISAU (2007) Boletim epidemioloógico do ministério da Saúde de Moçambique MISAU- Resultados da ronda serologica de 2007.
3. MISAU (2009) Boletim epidemiológico do ministério da Saúde de Moçambique MISAU- Resultados da ronda serologica.
4. INS/INE (2010) Inquérito Nacional de prevalência, riscos comportamentais e informação sobre o HIV e SIDA em Moçambique, Relatório 2010.
5. MOH, Ministry of health HIV/AIDS website (2010) Available: http://www.misau.gov.mz/pt/hiv_sida/dados_tarv_nacionais.Acessed: 2012 April 22.
6. WHO (2006) Guidelines for treatment and monitoring of HIV infection in resource limited settings.
7. MISAU (2010) Guia de tratamento da infeccao por HIV no aldulto e adolescente em Mocambique. Ministerio da Saude.
8. Auld A, Mbofana F, Shiraishi R, Sanchez M, Alfredo C, et al. (2011) Four-Year Treatment Outcomes of Adult Patients Enrolled in Mozambiqués Rapidly expanding antiretroviral Therapy Program. PLoS ONE Vol 6.
9. Abreu C, Brindeiro P, Martins A, Arruda M, Bule E, et al. (2008) Genotypic and phenotypic characterization of humanimmunodeficiency virus type 1 isolates circulating in pregnant women from Mozambique. In: Arch Virol. p 2013-2017.
10. Myatt M, Bennett D (2008) A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings. Antiviral Therapy Suppl 2: 37-48.
11. Bertagnolio S, Sutherland D, (2005) WHO approach to track HIV drug resistance emergence and transmission in countries scalling up HIV treatment. AIDS 19: 1329-1330.
12. Ayouba A, Lien t, Nouhin J, Vergne L, Aghokeng A, et al. (2009) Low prevalence of HIV Type 1 Drug resistance mutations in untreated, recently infected patients from Burkina Faso, Côte d́ Ivoire, Senegal, Thailand and Vietnam: The ANRS 12134 Study. AIDS Research and human Retrovirus 25: 11.
13. Pilay C, Bredell H, Mcintyre J, Gray G, Morris L, (2002) HIV-1 Subtype C Reverse Transcriptase Sequences from Drug-Naive Pregnant Women in South Africa AIDS. Research and human Retrovirus Volume 18: 605-610.
14. Maphalala G, Okello V, Mndzebele S, Gwebu P, Mulima N, et al. (2008) Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland in 2006. Antivir Therapy 13: 95-100.
15. Jayaraman GCAC, Kim J, Rekart ML, Singh AE, Harmen S, et al. (2006) A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr Vol. 42 86-90.
16. Oliveira KT, Deforche S, Cassol M, Salminem D, Paraskevis C, et al. (2005) An Automated Genotyping System for Analysis of HIV-1 and other Microbial Sequences. Bioinfomatics 21 3797-3800.
17. Tamura K, Dudley J, Nei M, Kumar S, (2007) MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol E vol 24: 1596-1599.
18. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S, (2011) MEGA5: Molecular Evolutionary Genetics Analysis using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods. Mol. Biol. E vol. 28: 2731-2739.
19. Mark M, Ernest G, Lionella F, Allison N, Saul G, et al. (2012) Semi-Quantitative Evaluation of Access and Coverage (SQUEAC)/Simplified Lot Quality Assurance Sampling Evaluation of Access and Coverage (SLEAC) Technical Reference. Brixton Health, Valid International, Action Against Hunger UK, Concern Worldwide, Tufts University., October.
20. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. (2009) Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update. PLos ONE vol 4: e 4724.
21. Gonzalez LMF, Brindeiro RM, Tarin M, Calazans A, Soares MA, et al. (2003) In Vitro Hypersusceptibility of Human Immunodeficiency Virus Type 1 Subtype C Protease to Lopinavir. Antimicrobial Agents and Chemotherapy 2817-2822.
22. Bellocchi MC, Forbici F, Palombi L, Gori C, Coelho E, et al. (2005) Subtype Analysis and Mutations to Antiviral Drugs in HIV-1-Infected Patients From Mozambique Before Initiation of Antiretroviral Therapy: Results From the DREAM Programme. Journal of Medical Virology 76 76: 452-458.
23. Dumans AT, Barreto CC, Santos AF, Arruda M, Sousa TM, et al. (2009) Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure. Infect Genet Evol 9: 62-70.
24. Perno CF, Cozzi-Lepri A, Balotta C, Bertoli A, Violin M, et al. (2002) Low prevalence of primary mutations associated with drug resistance in antiviral-naive patients at therapy initiation. Aids 16: 619-624.
25. Kamoto K, Aberle-Grasse J, (2008) Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antiviral therapy 13: 83-87.
26. Nyombi BM, Holm-Hansen C, Kristiansen KI, Bjune G, Müller F, (2008) Prevalence of reverse transcriptase and protease mutations associated with antiretroviral drug resistance among drug-naïve HIV-1 infected pregnant women in Kagera and Kilimanjaro regions,Tanzania AIDS Research and Therapy. 5: 13.
27. Bartolo I, Casanovas J, Bastos R, Rocha C, Abecasis A, et al. (2009) HIV-1 Genetic Diversity and Transmitted Drug Resistancein Health Care Settings in Maputo, Mozambique. In: J Acquir Immune Defic Syndr p323-331.